Skip to main content

Table 2 IFX concentration by age group

From: Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan

  6 to < 12 years 12 to 17 years
μg/mL, median (IQR) n μg/mL, median (IQR) n
1 h after administration at Week 0 92.87 (76.62, 107.71) 4 97.17 (91.53, 107.43) 17
Week 8 20.65 (12.00, 23.08) 3 28.34 (20.39, 35.03) 16
Week 14 0.85 (0.26, 3.45) 3a 3.11 (0.80, 6.06) 15a
Week 22 0.34 (0.33, 0.57) 3a 2.65 (0.48, 5.21) 12a
Week 30 1.20 (0.00, 1.48) 3a 2.62 (0.00, 5.78) 11a
  1. aWeek 8 CAI-based responders
  2. CAI Clinical activity index, IFX Infliximab